目的：研究瑞舒伐他汀与曲美他嗪联合治疗冠心病的应用价值。方法选择我院2014年1～6月收治的冠心病患者130例，随机分成研究组（n=65）与对照组（n=65），对照组采用瑞舒伐他汀治疗，研究组则在对照组的基础上加用曲美他嗪进行治疗，比较分析两组临床治疗效果。结果研究组治疗总有效率为96.9%，对照组的治疗总有效率为81.5%，两组治疗总有效率比较差异有统计学意义（P＜0.05）；治疗后，研究组患者的血脂水平与CRP指标均优于对照组（P＜0.05）。结论瑞舒伐他汀与曲美他嗪联合治疗冠心病的应用价值比较高，可以明显改善患者的血脂水平及CRP指标。%Objective To study the rosuvastatin and trimetazidine combined with coronary heart disease treatment application value.Methods 130 patients with coronary heart disease in our hospital from 2014 January to June, were randomly divided into study group (n=65) and control group (n=65), the control group using rosuvastatin treatment, study group on the basis of the control group were treated with trimetazidine, comparative analysis of the therapeutic effect of two groups of clinical.ResultsThe study group the total effective rate was 96.9%, treatment group total effectiveness is 81.5%, the two group total effectiveness comparisons have statistics significance (P<0.05), after treatment, blood lipid levels and CRP index in patients of the study group were signiifcantly better than the control group (P<0.05).Conclusion Rosuvastatin and trimetazidine treatment of coronary heart disease combined with relatively high value,can signiifcantly improve the patient's condition.
展开▼
